Sanofi

Apogee Therapeutics recently presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York, highlighting its pipeline to investors an...

BofA raised the firm’s price target on Teva (TEVA) to $38 from $37 and keeps a Buy rating on the shares after the company and partner Sanofi (SNY) announced Pha...

Innate Pharma SA ( (FR:IPH) ) has issued an update. Innate Pharma S.A., a clinical-stage biotech specializing in cancer immunotherapies and next-generation ant...

Sanofi SA (SNY) announced an update on their ongoing clinical study. The study “Prospective and Retrospective Observational Real-world Study to Characterize Pa...

Sanofi ( (SNY) ) just unveiled an update. On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for immune throm...

(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD...

Positive Data From Inflammatory Bowel Disease Study Teva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extens...

...

(RTTNews) - Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically sig...

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron are running a proof-of-concept Phase...